Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 5, 2005, Pages

  Bukirwa, Hasifa ^a   Orton, Lois C ^b  

^a MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; MEFLOQUINE; SESQUITERPENE;

CLINICAL TRIAL; DRUG COMBINATION; HUMAN; MALARIA FALCIPARUM; META ANALYSIS; REVIEW;

ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; MEFLOQUINE; SESQUITERPENES;

EID: 33644873632     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004531.pub2     Document Type: Article

References (42)

1. Karbwang J, Na Bangchang K, Thanavibul A, Back DJ, Bunnag D, Harinasuta T. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bulletin of the World Health Organization 1994;72(1):83-7.
2. Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Suntharasamai P, Charoenlarp P, et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet 1992;339(8797):821-4.
3. Marquino W, Huilca M, Calampa C, Falconi E, Cabezas C, Naupay R, et al. Efficacy of mefloquine and mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru. American Journal of Tropical Medicine and Hygiene 2003;68(5):608-12.
4. Pillai DR, Hijar G, Montoya Y, Marouino W, Ruebush TK 2nd, Wongsrichanalai C, et al. Lack of prediction of mefloquine and mefloquine-artesunate treatment outcome by mutations in the Plasmodium falciparum multidrug resistance 1 (pfmdr1) gene for P. falciparum malaria in Peru. American Journal of Tropical Medicine and Hygiene 2003;68(1):107-10.
5. Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Pah Eh J, Chongsuphajaisiddhi T, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. Journal of Infectious Diseases 1994;170(4):971-7.
6. Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Pah Eh J, Chongsuphajaisiddhi T, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. Journal of Infectious Diseases 1994;170(4):971-7.
7. Price RN, Nosten F, Luxemburger C, Kham A, Brockman A, Chongsuphajaisiddhi T, et al. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 1995;89(5):523-7.
8. Smithuis F, Shahmanesh M, Kyaw MK, Savran O, Lwin S, White NJ. Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North Myanmar. Tropical Medicine and International Health 2004;9(11):1184-90.
9. Thimasarn K, Sirichaisinthop J, Chanyakhun P, Palananth C, Rooney W. A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in Eastern Thailand. SouthEast Asian Journal of Tropical Medicine and Public Health 1997;28(3):465-71.
10. Adam I, A-Elbasit IE, Elbashir MI. Efficacies of mefloquine alone and of artesunate followed by mefloquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Annals of Tropical Medicine and Parasitology 2005;99(2):111-7.
11. Cardoso Bda S, Dourado HV, Pinheiro Mda C, Crescente JA, Amoras WW, Baena J, et al. An efficacy and tolerance study of oral artesunate alone and in combination with mefloquine in the treatment of umcomplicated falciparum malaria in an endemic area of Para, Brazil [Estudo da eficacia e tolerancia do artesunato oral isolado e em associacao com mefloquina, no tratamanto da malaria falciparum nao complicada em area endemica do Para, Brasil]. Revista da Sociedade Brasileira de Medicina Tropical 1996;29(3):251-7.
12. Looareesuwan S, Vanijanonta S, Viravan C, Wilairatana P, Charoenlarp P, Andrial M. Randomized trial of mefloquine alone and artesunate followed by mefloquine for the treatment of acute uncomplicated falciparum malaria. Annals of Tropical Medicine and Parasitology 1994;88(2):131-6.
13. Luxemburger C, ter Kuile FO, Nosten F, Dolan G, Bradol JH, Phaipun L, et al. Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88(2):213-7.
14. Price R, Luxemburger C, van Vugt M, Nosten F, Kham A, Simpson J, et al. Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 1998;92(2):207-11.
15. Angus BJ, Thaiaporn I, Chanthapadith K Suputtamongkol Y, White NJ. Oral artesunate dose-response relationship in acute falciparum malaria. Journal of the Medical Association of Thailand 2001;84(9):1289-99.
16. Bethell DB, Teja-Isavadharm P, Cao XT, Pham TT, Ta TT, Tran TN, et al. Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 1997;91(2):195-8.
17. Brewer GT, Peggins OJ, Grate JS, Petras JM, Levine BS, Weina PJ, et al. Neurotoxicity in animals due to arteether and artemether. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88 Suppl 1:33-6.
18. Gilles HM. Management of severe malaria: a practical handbook. 2nd Edition. Geneva: World Health Organization, 2000.
19. Higgins J, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions [updated March 2005]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 18 April 2005).
20. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: Postulation of "dormancy" a partial cystostatic effect of the drug, and its implication of treatment regimens. Parasitology 2000;121(3):237-46.
21. Jüni P, Altman DG, Egger M. Systematic reviews in healthcare: Assessing the quality of controlled trials. BMJ 2001;323(7303):42-6.
22. Kain KC. Chemotherapy and prevention of drug-resistant malaria. Wilderness & Environmental Medicine 1995;6(3):307-24.
23. Looareesuwan S, Harinasuta T, Chongsuphajaisiddhi T. Drug resistant malaria, with special reference to Thailand. Southeast Asian Journal of Tropical Medicine and Public Health 1992;23(4):621-34.
24. Looareesuwan S, Wilairatana P, Chokejindachai W, Viriyavejakul P, Krudsood S, Singhasivanon P. Research on new antimalarial drugs and the use of drugs in combination at the Bangkok Hospital for Tropical Diseases. Southeast Asian Journal of Tropical Medicine and Public Health 1998;29(2):344-54.
25. McIntosh HM, Olliaro P. Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 1999, Issue 2. [DOI: 10.1002/14651858.CD000256]
26. McIntosh HM, Olliaro P. Artemisinin derivatives for treating severe malaria. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000527]
27. Olliaro O, Cattani J, Wirth D. Malaria, the submerged disease. JAMA 1996;275(3):230-3.
28. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996;347(9016):1654-8.
29. Global Partnership to Roll Back Malaria. Combination therapy with antimalarial drugs. Antimalarial drug combination therapy: report of a WHO technical consultation, 4-5 April 2001. Geneva: World Health Organization, 2001:7-8.
30. Global Partnership to Roll Back Malaria. 2.2 Rationale for the use of combination therapy & 2.3 Artemisinin-based combination therapy. The use of antimalarial drugs: report of a WHO informal consultation, 13-17 November 2000. Geneva: World Health Organization, 2001:17-9.
31. Global Partnership to Roll Back Malaria. Artemisinin-based combinations. The use of antimalarial drugs: Report of a WHO informal consultation, 13-17 November 2000. Geneva: World Health Organization, 2001:12-5.
32. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
33. Trung TN, Davis TM, Hewitt S, Thuan LK, Quang HH, Anh CV, et al. Treatment of falciparum malaria in Vietnamese children: the need for combination therapy and optimized dosage regimens. Annals of Tropical Paediatrics 2001;21(4):307-12.
34. Weinke T, Trautmann M, Helh T, Weber G, Eichenlaub D, Fleischer K, et al. Neuropsychiatric side effects after the use of mefloquine. American Journal of Tropical Medicine and Hygiene 1991;45(1):86-91.
35. White NJ. Can amodiaquine be resurrected?. Lancet 1996;348(9036):1184-5.
36. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrobial agents and chemotherapy 1997;41(7):1413-22.
37. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet 1999;353(9168):1965-7.
38. World Health Organization/AFRO. Malaria. www.afro.who.int/malaria/bulletins/2001 (accessed 12 March 2003).
39. World Health Organization. Regional Office for Western Pacific. Report: meeting on antimalarial drug development / convened by: World Health Organization, Regional Office for the Western Pacific, Shanghai, China 16-17 November 2001. Manila: WHO Regional Office for the Western Pacific, 2002.
40. World Health Organization, Roll Back Malaria Dept. Guidelines for the treatment of malaria [WHO/HTM/MAL/2006.1108]. Geneva: World Health Organization, 2006.
41. World Health Organization. Malaria Control Unit, UNICEF. The Africa Malaria Report 2003. Geneva: World Health Organization, 2003.
42. Wongsrichanalai C, Picjard AL, Wersdorfer WH, Meshnick SR. Epidemiology of drug resistant malaria. Lancet Infectious Diseases 2002;2(4):209-18.